Natixis Advisors LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Natixis Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% in the 4th quarter, HoldingsChannel reports. The firm owned 122,588 shares of the biopharmaceutical company’s stock after acquiring an additional 2,479 shares during the quarter. Natixis Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $94,622,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. WPG Advisers LLC raised its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Entrust Financial LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $32,000. Torren Management LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $38,000. Finally, FNY Investment Advisers LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Analyst Ratings Changes

REGN has been the topic of several analyst reports. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $900.00 to $700.00 in a research report on Monday, May 18th. Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Stock Up 0.4%

REGN stock opened at $602.92 on Wednesday. The firm’s fifty day moving average is $716.42 and its 200 day moving average is $744.46. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The firm has a market cap of $63.74 billion, a PE ratio of 14.69, a P/E/G ratio of 1.33 and a beta of 0.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the business earned $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be given a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.